XENPOZYME (OLIPUDASE ALFA-RPCP)
XENPOZYME (OLIPUDASE ALFA-RPCP) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: XENPOZYME; Generic name: OLIPUDASE ALFA-RPCP; Manufacturer: Genzyme Corporation.
| Brand name | XENPOZYME |
|---|---|
| Generic name | OLIPUDASE ALFA-RPCP |
| Manufacturer | Genzyme Corporation |
| Used for | 1 INDICATIONS AND USAGE XENPOZYME is indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients. XENPOZYME is a hydrolytic lysosomal sphingomyelin-specific enzyme indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients. ( 1 ) |
| Dosage | 2 DOSAGE AND ADMINISTRATION See Full Prescribing Information for important recommendations prior to XENPOZYME treatment initiation. ( 2.1 ) Adults: Recommended starting dose is 0.1 mg/kg administered as an intravenous infusion. ( 2.2 ) Pediatrics: Recommended starting dose is 0.03 mg/kg administered as an intravenous infusion. ( 2.3 ) See Full Prescribing Information for the recommended dose escalation and maintenance dosage, dosage modifications to reduce the risk of adverse reactions, and prep |
| Warnings | WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with XENPOZYME have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment, should be readily available during XENPOZYME administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue XENPOZYME immediately and initiate appropriate medical treatment. In patients with |
| Active ingredient(s) | OLIPUDASE ALFA |
| Route | INTRAVENOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01a910ee-a33e-4be3-ac41-322d64c34311 |